NextGen Group plc ('NextGen' or the 'Company')

Related Party Transaction

Further to the announcement made on 27 November 2008 regarding the placing of new   ordinary shares of 0.1 pence each in the Company, which raised £639,000 before expenses, the Company announces that, pursuant to a board resolution at the time of the placing, it is to pay placing commission of 9 per cent to Nanotecquity AG ('Nanotecquity') for its services in connection therewith.  Klaus Rosenau is a director of both Nanotecquity and the Company, and Nanotecquity and the Company have 3 mutual shareholders which between them own almost 100% of Nanotecquity and just under 20% of the Company. Accordingly, the payment of commission to Nanotecquity comprises a related party transaction pursuant to the AIM Rules. The Directors of NextGen (other than Klaus Rosenau), have consulted with the Company's Nominated Adviser, Seymour Pierce Limited, to consider that the payment of the placing commission to Nanotecquity, is fair and reasonable insofar as the Company's shareholders are concerned.

Enquiries:

Notes to Editors

NextGen Group PLC www.nextgensciences.com

NextGen Group PLC is a provider of biomarker services for pharmaceutical and biotech companies globally. A biomarker is a substance (e.g. a protein) used as an indicator of a biologic state. A biomarker can be measured from a clinical sample, such as blood or urine, and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.  The Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients. 

NextGen's range of services, which include biomarker testing, discovery and assay development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.